A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Phase of Trial: Phase III
Latest Information Update: 12 Mar 2018
At a glance
- Drugs Eribulin (Primary) ; Capecitabine
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Eisai Inc
- 16 Jan 2018 Status changed from active, no longer recruiting to completed.
- 01 Sep 2017 Planned End Date changed from 1 Dec 2016 to 30 Dec 2017.
- 16 Jun 2016 Planned End Date changed from 1 Feb 2015 to 1 Dec 2016.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History